Introduction
In 1955 ± 1957 two scienti®c groups identi®ed a new substance with a role in electron transport in the cells. Festenstein et al (1955) named the substance ubiquinone, while Crane et al (1957) chose the name coenzyme Q.
The name ubiquinone means`ubiquitous quinone' and relates to the presence of the substance in all cells. The name coenzyme Q refers to the chemical structure and in coenzyme Q 10 , the human form, the molecule contains one quinone group and 10 isoprenyl units. Chemically Q 10 is designated 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone ( Figure 1 ). In this review the abbreviation`Q 10 ' will be used. Q 10 acts as an electron carrier in the mitochondrial electron transport chain. This aspect will not be in focus in the present review, which concentrates on the health effects and the safety of Q 10 as a dietary supplement.
It is characteristic that the major part of the results of the early studies regarding Q 10 were not published in recognised scienti®c journals, but in separate reports mostly from international symposia. Therefore, part of this literature is not registered in the scienti®c reference data systems. Several of the studies concerning Q 10 in relation to diseases are not well controlled and conclusions have often been drawn on insuf®cient data.
Biochemistry and physiological effects
The biosynthesis of Q 10 involves three major steps (Olson & Rudney, 1983 ) Ð synthesis of the ring structure from the essential amino acids tyrosine or phenylalanine, formation of the isoprenoid side chain from acetyl-CoA residues via the mevanolate pathway, and ®nally condensation of these structures by means of the enzyme polyprenyl-transferase, possibly in the Golgi apparatus. An essential step regulating the synthesis seems to be the hydroxymethylglutaryl (HMG)-coenzyme A reductase reaction, common with a step in cholesterol synthesis, but other steps may also be regulated ( Figure 2 ).
As mentioned, Q 10 plays an important role as electron and proton transporter in the mitochondria. Circumstances which change the quantity of Q 10 in the inner mitochondrial membrane correspondingly change the electron transport rate, thus in¯uencing the ef®cacy of the ATP production. Q 10 exists both in an oxidised and a reduced form, ubiquinone and ubiquinol, respectively. Therefore Q 10 also has a role as a lipid soluble antioxidant. Several studies have described reduced LDL oxidation in vitro and in vivo after Q 10 supplementation (Alleva et al, 1995; Kaikkonen et al, 1997) . A sparing effect on vitamin E as well as a direct anti-oxidative effect has been reported (Stocker et al, 1996) .
Occurrence
Coenzyme Q has been found in both microorganisms and plants, as well as in animals. Q 10 is the most prevalent form in humans and most mammals (Ramasarma et al, 1985) . However, Q 9 is the primary form found in rats and mice. Q 6, Q 7 and Q 8 are found in yeast and bacteria.
Q 10 is present in most tissues, but in varying amounts. The highest concentrations in human tissues are found in heart, liver and kidney, approximately 110, 60 and 70 mgag tissue, respectively, and the lowest concentration, 8 mgag, in lung tissue (Ernster & Forsmark-Andre Âe, 1993) . The major part is in the reduced form, except in brain and lung tissue.
In numerous studies the amount of Q 10 in human plasma has been found to be in the range of 0.75 ± 1.00 mgaml, of which 75% is in the reduced form (Ernster & ForsmarkAndree Â, 1993) . Q 10 is thought to be primarily bound to LDL . The total content in the body is estimated to 1.0 ± 1.5 g, most of this being found in muscle cells (Karlsson et al, 1993; Gale et al, 1961) . It has been reported that the Q 10 levels in humans decline with age (Ernster & Forsmark-Andree, 1993) .
Tissue Q 10 originates from endogenous synthesis as well as from food intake and from oral supplements. A survey of the amount of coenzyme Q in selected food items is given in Table 1 . There are substantial variations in the values, which may be due to differences in analytical methodology and differences in species as well as seasonal variations. Prepared foods were found to have values 15 ± 30% lower than similar raw products (Weber et al, 1997) .
Based on food frequency studies in 1985 and 1995 by the National Food Agency of Denmark, the dietary intake of Q 10 was estimated to be 3 ± 5 mgad in Denmark. The intake of Q 9 was around 1 mgad (Weber et al, 1997) .
A recommended daily intake has not yet been determined. The manufacturers of supplements recommend an intake of 10 ± 30 mgad for healthy individuals. In the general population no proven de®ciency symptoms have yet been reported, thus it can be assumed that a varied diet and a normal in vivo synthesis will supply suf®cient Q 10 to healthy individuals.
Pharmacology
Studies of Q 10 's pharmacology have been complicated by the fact that Q 10 is both synthesised in the body and obtained from food. Tomono et al (1986) by-passed this dif®culty as they studied the pharmacokinetics using The values represent means of triplicate measurements. The range of different samples is given in parentheses. The s.d. of the analysis was 6.2% , ranging from 2.3% to 9.3%. When no Q 10 peak was seen in the chromatogram the detection limit for the analysis is given. n.d.: below detection limit.
Coenzyme Q 10 in health and disease K Overvad et al deuterium-labelled Q 10 in 16 healthy volunteers. Following intake of 100 mg Q 10, blood values reached a maximum after approximately 6 h, indicating a relatively slow absorption which relates to the high molecular weight and the lipid solubility of Q 10. In most of the subjects a secondary peak was found in the blood 24 h after intake, which is explained by absorption in the liver and subsequent redistribution via VLDL. The plasma half-life was about 33 h. The administered Q 10 dose did not affect the plasma levels of endogeneous synthesised Q 10 for up to 72 h after intake. The formulation of Q 10 was not described. After intakes of 3620 mg Q 10 per day for 4 d, in six different formulations an increase in the plasma level of up to 2.8 times the baseline level was observed. Q 10 dissolved in oil and formulated as capsules appears to have the best bioavailability. Mohr et al (1992) found increased levels of Q 10 in lipoproteins after oral supplementation and also an incresed resistance of LDL to incipient lipid peroxidation.
Increased myocardial tissue content of Q 10 via exogenously administered Q 10 has been shown both in animal experiments (Crestanello et al, 1996) and in man . After a supplementation period of 5 months with Q 10 100 mgad in patients with cardiomyopathy, the percentage increases of Q 10 in the myocardium ranged from 19 to 86% (endomyocardial biopsies).
Case reports have suggested interaction between Q 10 and warfarin. In pigs a thrombocyte anti-aggregating effect has been found after chronic dosing of 200 ± 400 mgad.
Some studies suggest relatively low Q 10 concentration in the myocardium after administration of anthracyclines, and other studies suggest that Q 10 administration may reduce the cardiotoxicity of anthracyclines (Karlsson et al, 1986) .
Most of the widely used HMG-coenzyme A-reductase inhibitors, which inhibit cholesterol synthesis, result in reduced synthesis and thereby reduced Q 10 levels in plasma (Bargossi et al, 1994) . This dose-related decrease is true for, among others, lovastatin and pravastatin (Mortensen et al, 1997). The signi®cance of this is not known; however, the impaired biosynthesis and consequent Q 10 downregulation deserves further evaluation in long-term trials considering the oxidative theory for the development of atherosclerosis.
In placebo-controlled long-term studies no serious or frequent side effects to intake of doses of 200 mg Q 10 ad for up to 12 months and 100 mg Q 10 ad for up to 6 y have been found. However, none of the controlled studies were speci®cally designed to examine possible side effects.
Physical capacity
Relatively low blood levels of Q 10 in individuals at high levels of physical activity have been demonstrated (Karlsson et al, 1993) . One study showed a positive association between blood levels of Q 10 and maximal oxygen uptake (Battino et al, 1997) , and non-randomised experimental studies have suggested that supplementation with Q 10 has a positive effect on physical capacity (Vanfraechem et al, 1986; Yamabe & Fukuzake, 1991) . However, several of the experiments did not include a reference group, and placebo effect, information bias and confounding may have in¯u-enced the results.
Several randomised experimental studies on Q 10 supplementation and physical capacity have been undertaken (Braun et al, 1991; Snider et al, 1992; Porter et al, 1995; Laaksonen et al, 1995; Malm et al, 1997; Weston et al, 1997; Ylikoski et al, 1997) . Out of 11 studies, ®ve indicated a positive effect of Q 10 on physical capacity, ®ve indicated no effect and one study a negative effect of Q 10 . The differences in the results could not be explained by differences in gender, age nor levels of physical capacity prior to supplementation. The results of the best studies, from a methodological point of view, indicated no effect of Q 10 .
One of the experimental studies found an increase in creatine kinase levels in the blood after intake of a Q 10 supplement (Malm et al, 1996) . This may be due to increased cell damage. However, these results were not supported by other studies, where the creatine kinase levels were unchanged during Q 10 supplementation. Other major side effects were not reported from the studies on Q 10 and physical capacity.
The experimental studies so far have not clari®ed the importance of Q 10 in physical capacity.
Heart failure
At the cellular level, oxidative stress, mitochondrial dysfunction and energy starvation are supposed to play important pathophysiological roles in heart failure. When compared to normal subjects, reduced blood and myocardial tissue content of Q 10 has been detected in heart failure and in endomyocardial tissue samples from patients with dilated cardiomyopathy (Mortensen, 1989) . The level of blood and myocardial Q 10 was negatively associated with the severity of symptoms and the degree of left ventricular dysfunction.
The importance of Q 10 treatment in heart failure has initially been examined in patients with dilated cardiomyopathy. This is a severe disease, mainly affecting men around 40 years of age. The incidence rate is about 30 ± 100 cases per million per year in the Western World. The lethality is around 50% at 2 y and a substantial number may be heart transplant candidates.
Several open treatment experiments have suggested positive effects of Q 10 supplements in patients with severe heart failure (NYHA classes III and IV). Nine relevant randomised double-blind placebo-controlled studies concerning treatment of heart failure of various etiologies with Q 10 were published between 1985 and 1995 (Table 2 ). In eight of these studies signs of improvement in clinical parameters, haemodynamic parameters andaor exercise capacity were registered when conventional treatment was accompanied by Q 10 supplementation. The studies primarily included patients with advanced heart failure.
The existing randomised, controlled studies are not suf®ciently large to indicate any changes in mortality in the Q 10 -treated group and studies with the primary endpoint of mortality are required. However, Q 10 is devoid of signi®cant side-effects and for patients with heart failure an improvement of 1 ± 2 NYHA classes may constitute a signi®cantly improved quality of life.
Acute myocardial infarction
In a recent randomised experiment supplementation with Q 10 reduced development of angina pectoris, arrhythmias and ventricular dysfunction in patients with acute myocardial infarction (Singh et al, 1998 ).
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Angina pectoris
In animal models Q 10 prevents the damage that occurs when the blood supply to the myocardium is reduced for a brief period. This observation is the basis for ®ve randomised, double-blind, placebo-controlled experiments examining Q 10 's effect on angina pectoris in humans (Table 3) . The studies differed in study design, Q 10 dosage and treatment period. In four of these studies there are problems with the randomisation, blinding and evaluation of the results. Generally the studies found that Q 10 increased the patients' stamina during exercise on a treadmill or an exercise bike, delaying the development ST depression as a sign of oxygen de®ciency in the myocardium, and delaying the onset of angina pectoris. Several of the studies found that fewer angina pectoris attacks were provoked and that daily use of nitroglycerine was reduced. However, larger, long-term studies are necessary to con®rm these observations.
Hypertension
Several non-controlled experiments concerning th effect of Q 10 supplementation on high blood pressure in humans have been conducted. With one exception all these studies found that Q 10 supplementation decreased blood pressure. (Yamagami et al, 1986) ; Digiesi et al, 1990) . Both systolic and diastolic blood pressure were reduced. Further investigations are clearly necessary before Q 10 's potential in the treatment of high blood pressure is fully explored.
Cardiac and vascular surgery
Several experiments have described the effect of Q 10 supplement on different clinical, haemodynamical and biochemical parameters in connection with cardiac surgery for ischemic heart disease or valvular heart disease (Chello et al, 1994; Judy et al, 1993) . In one controlled doubleblind study of patients with peripheral vascular disease, Chello et al found less enzyme leakage (creatinekinase and lactatedehydrogenase) and lower levels of split products of the oxidative burst in the Q 10 pre-treated patients (Chello et al, 1996) . Separately the experiments support the notion that pre-treatment of the patients with Q 10 for at least one week may have favourable effects. Long-term survival studies with larger patient groups are relevant.
Cancer diseases
Animal experiments have suggested that Q 10 plays a role in the blood cell formation and in the function of the immune system. This has been the rationale for studies on Q 10 and cancer.
Folkers et al compared the Q 10 content in blood from patients with various cancerous diseases to blood levels in an unspeci®ed reference group (Folkers et al, 1991) . The Q 10 content was lower in blood from the cancer patients than in the reference subjects. It is not possible to determine whether this is causal or a consequence of the disease.
In one open treatment experiment, 32 patients with breast cancer received, concomitant with their conventional treatment, a supplement consisting of Q 10 , other antioxidants and essential fatty acids (Lockwood et al, 1994) . Based on national life expectancy data for breast cancer patients, four deaths were predicted in the treated group. All the subjects survived an 18-month follow-up period. A speci®c effect of Q 10 cannot be determined from this study because several different treatments are administered at the same time. It is further unlikely that the subjects entering the experiment are a random sample of patients with breast cancer and confounding is therefore probable.
There is little scienti®c evidence to support the hypothesis that Q 10 should play a preventive role in the aetiology of cancer. Both the case-referent experiment and the treatment experiment discussed are inconclusive.
Parodontal disease
It is known that the level of Q 10 in the gingiva declines with age, and that the frequency of parodontal disease increases. Seven studies have described the effect of Q 10 on parodontal disease. The studies differed in the choice of patient populations, Q 10 administration and aims. None of the three randomised, placebo controlled, double-blind experiments demonstrated positive effects of Q 10 (Wilkinson et al, 1976) ; Iwamoto et al, 1981; Glavind et al, 1994) .
Hanioka et al administered Q 10 locally in each gingiva pocket (Hanka et al, 1994) . The experimental method is unfortunately insuf®ciently described. It is not stated whether the experiment was blinded, nor is information given on how the Q 10 was injected and what dose was given. The observed differences in gingival index and gingival bleeding were small, but as a pilot study the experiment is of interest and the method warrants further investigation.
Diseases in the nervous system Q 10 has been used alone and in combination with other agents in the treatment of patients with muscular dystrophy. Relevant statistical analysis revealed no effect of the Q 10 treatment (Folkers & Simonsen, 1995) .
Q 10 and male fertility Q 10 is important in energy production and in prevention of oxidative damage. Energy production and low levels of oxidation are important in sperm motility and function. A recent study demonstrated a positive correlation between Q 10 levels and sperm counts in seminal plasma and negative correlations with hydroperoxide levels (Lewin & Laron, 1997) . Further, Q 10 seems to increase sperm motility in sperm samples initially demonstrating low motility (Alleva et al, 1997) .
Use of Q 10 supplements in Denmark
In connection with this review the Danish Nutrition Council commissioned a telephone interview survey of the consumption of Q 10 in the Danish population.
Data were collected by telephone interviews during February 1996. A random sample of 1,800 individuals of more than 15 years of age was drawn from the CPR register. Non-respondents comprised 143 who did not have a telephone, 326 who did not wish to take part and 304 who did not answer the telephone. In all, 1,027 individuals (62%) were interviewed.
Seventy percent of the interviewees stated that they had heard of Q 10. Approximately 6% (95% con®dence limits 4 ± 7%) of the interviewees were currently taking a Q 10 supplement. A larger proportion of the interviewees, 17% had previously taken Q 10 . Tendencies in gender and age distribution were similar to those regarding current use of Q 10 supplements. Reasons given for taking a Q 10 supplement were: 43% hoped for better well-being, 34% hoped to feel more energetic and 23% hoped to affect a speci®c disease. Almost all the disorders discussed in this review were found in this last group. The most frequent disorder reported was parodontal disease (14 individuals).
